AOD-9604 vs MOTS-c

Fat loss peptides differ in origin and action. AOD-9604 and MOTS-c both appear in metabolic research. They are different in origin, mechanism, and logic. Both link to fat metabolism, but through distinct paths. This requires a look at molecular details.

AOD-9604 is a fragment of human growth hormone. It uses amino acids 177-191 of the GH molecule. This region causes GH's fat-reducing effects. It lacks growth and insulin effects. Isolating this 15-amino-acid fragment gives lipolytic activity. It avoids IGF-1, insulin resistance, and growth effects of full GH [PMID: 11713213].

MOTS-c takes a different approach. It is a 16-amino-acid peptide. It is encoded in mitochondrial DNA. It sits in the 12S rRNA gene. First shown by Lee et al. in 2015, MOTS-c is a new class. These are mitochondrial-derived peptides (MDPs). They move to the nucleus under stress. There they reprogram gene expression [PMID: 25565208]. The peptide's target is AMPK. AMPK is an energy-sensing enzyme. The peptide activates AMPK to improve insulin sensitivity. It also raises glucose use and fat oxidation.

One peptide is a scalpel. It stimulates fat breakdown via adrenergic signaling. The other is a thermostat. It senses energy use and reprograms cell metabolism. Comparing the two shows two strategies for excess fat in research models.

AOD-9604 uses the beta-3-adrenergic receptor path. This receptor sits on white fat tissue. The 177-191 fragment of growth hormone appears to raise lipolysis. It makes fat cells more sensitive to catecholamine signals. The receptor triggers hormone-sensitive lipase (HSL) and perilipin. These break down fat droplets and release fatty acids [PMID: 11146367].

AOD-9604 does this without using the GH receptor or IGF-1. In preclinical studies, the peptide raised fat use and cut body fat in obese mice. It did not change blood glucose, insulin, or IGF-1 [PMID: 25565208]. This is the point of the fragment. It keeps the lipolytic signal and drops GH side effects.

MOTS-c works through different logic. As a mitochondrial peptide, it links energy sensing and nuclear gene control. When cell energy drops, the peptide moves to the nucleus. There it acts as a gene regulator. It raises the AMPK path and shifts folate-cycle work [PMID: 25565208].

AMPK use by MOTS-c has many effects. It raises glucose use via GLUT4. It raises fat oxidation. It cuts fat build and blocks mTOR. mTOR is a growth path. In diet-induced obesity models, the peptide stopped weight gain. It raised glucose use and insulin sensitivity. It did not cut food use. These gains needed AMPK. Without AMPK, the peptide's effects vanished [PMID: 27060479].

The two paths differ. AOD-9604 acts on fat cells via adrenergic receptors. MOTS-c reprograms cell work to favor fat use. One is a command to break down fat. The other shifts how the body uses energy.

Both peptides link to fat loss in preclinical work. Both act without the full GH-IGF-1 axis. This is key. Neither causes insulin resistance, fluid build, or growth. Full GH can cause these in metabolic work.

Both are small peptides. AOD-9604 has 15 amino acids and MOTS-c has 16. Both can be injected under the skin. Both clear fast. AOD-9604 lasts 2-3 hours. MOTS-c lasts minutes. Both need frequent use to keep their work.

Both work mainly in preclinical models. These include mouse obesity and metabolic syndrome. Neither has run large human fat-loss trials. Both are second-generation work. They move past blunt use of GH or insulin. They use more specific metabolic tools.

Both use paths that exist in the body. AOD-9604 copies a natural GH piece. MOTS-c is a natural mitochondrial product. Neither adds foreign drugs. They raise or copy signals the body already uses.

The two have different origins and identity. AOD-9604 is a synthetic piece of nuclear growth hormone. It uses amino acids 177-191. MOTS-c sits in mitochondrial DNA. It is in the 12S rRNA gene. These are nuclear and mitochondrial genomes. They have different histories.

The core path is the main difference. AOD-9604 works through beta-3-adrenergic receptors on fat cells. It acts on lipolytic enzymes like HSL and perilipin. MOTS-c uses AMPK and gene work. It shifts the whole body toward fat use. AOD-9604 is a direct lipolytic signal. MOTS-c changes the metabolic setting.

Glucose and insulin effects split here. AOD-9604 does not affect glucose or insulin. It cuts body fat without changing blood sugar. This is its main edge as a GH piece. MOTS-c raises insulin use and glucose work. It uses AMPK and GLUT4. This makes it fit for metabolic syndrome work. It is not just for fat loss [PMID: 27060479].

The scope of work differs. AOD-9604 acts on fat only. MOTS-c has wider effects. It raises exercise work, insulin use, and metabolic work. These go past fat to muscle and liver. MOTS-c works on the whole body. AOD-9604 acts on fat alone.

Exercise links differ. MOTS-c raises run work in young and old mice. This shows it can raise exercise fit. It is good for exercise-mimetic work. AOD-9604 has no known exercise link. It acts on rest fat use only.

Research depth differs. AOD-9604 has run since the early 2000s. Its main path is from Ng et al. [PMID: 27060479]. MOTS-c is new, first shown in 2015. But it has grown fast. It has clear AMPK links, folate work, and nucleus moves. This is the one area where they compete. Even here, new has not meant weak.

Use AOD-9604 if your work targets fat breakdown. It does not touch glucose use or insulin. Its GH piece design fits fat study in isolation. It gives a clean lipolytic signal. It lacks full GH side effects. It also works when you need no insulin change. This is key in models that need no blood sugar change.

Use MOTS-c if your work targets whole-body metabolic gain. It is not just for fat. It raises insulin use, glucose work, and exercise fit. MOTS-c uses AMPK to act on the setting. This includes insulin resistance and poor fat use. It goes past the sign, which is excess fat. It fits work on metabolic syndrome, age work loss, and exercise mimetics.

For pure fat work with no other issues, AOD-9604 is the clear tool. For work where fat comes from poor metabolic work, use MOTS-c. It acts on the source, not the sign.

Neither peptide should give big weight loss on its own. These are preclinical models. They are metabolic tools, not appetite cutters. Their value is in path work on fat.